These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 25593116)

  • 1. Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial.
    Marincek N; Radojewski P; Dumont RA; Brunner P; Müller-Brand J; Maecke HR; Briel M; Walter MA
    J Nucl Med; 2015 Feb; 56(2):171-6. PubMed ID: 25593116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 90Y-DOTATOC as a Therapeutic Option for Complex Recurrent or Progressive Meningiomas.
    Gerster-Gilliéron K; Forrer F; Maecke H; Mueller-Brand J; Merlo A; Cordier D
    J Nucl Med; 2015 Nov; 56(11):1748-51. PubMed ID: 26294303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards tailored radiopeptide therapy.
    Radojewski P; Dumont R; Marincek N; Brunner P; Mäcke HR; Müller-Brand J; Briel M; Walter MA
    Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1231-7. PubMed ID: 25792454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake.
    Seystahl K; Stoecklein V; Schüller U; Rushing E; Nicolas G; Schäfer N; Ilhan H; Pangalu A; Weller M; Tonn JC; Sommerauer M; Albert NL
    Neuro Oncol; 2016 Nov; 18(11):1538-1547. PubMed ID: 27106404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study.
    Eigler C; McDougall L; Bauman A; Bernhardt P; Hentschel M; Blackham KA; Nicolas G; Fani M; Wild D; Cordier D
    J Nucl Med; 2024 Apr; 65(4):573-579. PubMed ID: 38423782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC.
    Forrer F; Uusijärvi H; Storch D; Maecke HR; Mueller-Brand J
    J Nucl Med; 2005 Aug; 46(8):1310-6. PubMed ID: 16085587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma.
    Bartolomei M; Bodei L; De Cicco C; Grana CM; Cremonesi M; Botteri E; Baio SM; Aricò D; Sansovini M; Paganelli G
    Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1407-16. PubMed ID: 19319527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival after somatostatin based radiopeptide therapy with (90)Y-DOTATOC vs. (90)Y-DOTATOC plus (177)Lu-DOTATOC in metastasized gastrinoma.
    Dumont RA; Seiler D; Marincek N; Brunner P; Radojewski P; Rochlitz C; Müller-Brand J; Maecke HR; Briel M; Walter MA
    Am J Nucl Med Mol Imaging; 2015; 5(1):46-55. PubMed ID: 25625026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas.
    Bodei L; Handkiewicz-Junak D; Grana C; Mazzetta C; Rocca P; Bartolomei M; Lopera Sierra M; Cremonesi M; Chinol M; Mäcke HR; Paganelli G
    Cancer Biother Radiopharm; 2004 Feb; 19(1):65-71. PubMed ID: 15068613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
    Kwekkeboom DJ; Kooij PP; Bakker WH; Mäcke HR; Krenning EP
    J Nucl Med; 1999 May; 40(5):762-7. PubMed ID: 10319747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of radiolabelled somatostatin analogues (
    Medina-Ornelas SS; García-Pérez FO
    Rev Esp Med Nucl Imagen Mol; 2017; 36(3):166-174. PubMed ID: 27890514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients.
    Versari A; Sollini M; Frasoldati A; Fraternali A; Filice A; Froio A; Asti M; Fioroni F; Cremonini N; Putzer D; Erba PA
    Thyroid; 2014 Apr; 24(4):715-26. PubMed ID: 24102584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient.
    Kulkarni HR; Schuchardt C; Baum RP
    Recent Results Cancer Res; 2013; 194():551-9. PubMed ID: 22918782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours.
    Romer A; Seiler D; Marincek N; Brunner P; Koller MT; Ng QK; Maecke HR; Müller-Brand J; Rochlitz C; Briel M; Schindler C; Walter MA
    Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):214-22. PubMed ID: 24085501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetes Mellitus and Its Effects on All-Cause Mortality After Radiopeptide Therapy for Neuroendocrine Tumors.
    Umlauft M; Radojewski P; Spanjol PM; Dumont R; Marincek N; Kollar A; Brunner P; Beyersmann J; Müller-Brand J; Maecke HR; Laimer M; Walter MA
    J Nucl Med; 2017 Jan; 58(1):97-102. PubMed ID: 27635023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas.
    Merlo A; Hausmann O; Wasner M; Steiner P; Otte A; Jermann E; Freitag P; Reubi JC; Müller-Brand J; Gratzl O; Mäcke HR
    Clin Cancer Res; 1999 May; 5(5):1025-33. PubMed ID: 10353735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors.
    Menda Y; O'Dorisio MS; Kao S; Khanna G; Michael S; Connolly M; Babich J; O'Dorisio T; Bushnell D; Madsen M
    J Nucl Med; 2010 Oct; 51(10):1524-31. PubMed ID: 20847174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toward radioguided surgery with β- decays: uptake of a somatostatin analogue, DOTATOC, in meningioma and high-grade glioma.
    Collamati F; Pepe A; Bellini F; Bocci V; Chiodi G; Cremonesi M; De Lucia E; Ferrari ME; Frallicciardi PM; Grana CM; Marafini M; Mattei I; Morganti S; Patera V; Piersanti L; Recchia L; Russomando A; Sarti A; Sciubba A; Senzacqua M; Solfaroli Camillocci E; Voena C; Pinci D; Faccini R
    J Nucl Med; 2015 Jan; 56(1):3-8. PubMed ID: 25500828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial.
    Pless M; Waldherr C; Maecke H; Buitrago C; Herrmann R; Mueller-Brand J
    Lung Cancer; 2004 Sep; 45(3):365-71. PubMed ID: 15301877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraoperative somatostatin receptor detection after peptide receptor radionuclide therapy with (177)Lu- and (90)Y-DOTATOC (tandem PRRNT) in a patient with a metastatic neuroendocrine tumor.
    Todorović-Tirnanić M; Kaemmerer D; Prasad V; Hommann M; Baum RP
    Recent Results Cancer Res; 2013; 194():487-96. PubMed ID: 22918778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.